Stay updated on Gilteritinib Combo with IDH Inhibitors in AML Clinical Trial
Sign up to get notified when there's something new on the Gilteritinib Combo with IDH Inhibitors in AML Clinical Trial page.

Latest updates to the Gilteritinib Combo with IDH Inhibitors in AML Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.3%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe web page has been updated to version 2.15.0, replacing the previous version 2.14.4.SummaryDifference1.0%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to March 5, 2025.SummaryDifference0.7%
- Check59 days agoChange DetectedThe study of Gilteritinib in combination with Ivosidenib or Enasidenib for Acute Myeloid Leukemia has been updated to reflect a new date of March 5, 2025, replacing the previous date of November 12, 2024.SummaryDifference2%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check88 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference6%
Stay in the know with updates to Gilteritinib Combo with IDH Inhibitors in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Gilteritinib Combo with IDH Inhibitors in AML Clinical Trial page.